Trials / Completed
CompletedNCT03594877
Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients
Effectiveness of the Sublimated Mare Milk on the Gut Microbiome in Psoriasis and Healthy Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Nazarbayev University Medical Center · Academic / Other
- Sex
- All
- Age
- 30 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates the effect of dietary supplement consisting of sublimated mare milk on intestinal microbiota among psoriasis and healthy participants.
Detailed description
The gut microbiome is believed to play an important role in the immune system regulation, since intestines are the largest lymphoid organ in a human body. Deviations from healthy composition of intestinal flora are associated with various diseases including allergy and autoimmunity. Psoriasis is the one of the long-lasting autoimmune diseases that is characterized by patches on the skin and further health complications throughout the life. However, lack of studies does not allow proper evaluation of role of gut microbiome in psoriasis patients. Therefore, potential interplay between gut microbiome and immune system in psoriasis would be studied in this clinical trial. Particularly, the investigators hypothesize that sublimated mare milk supplement can have an impact on gut immune system and gut microbiome composition in the psoriasis patients. In this trial, there will be two parallel groups: crossover psoriasis patients (standard treatment first for 3 months, next 3 months standard treatment plus sublimated mare milk supplement) and healthy volunteers group. Subsequently, association of intestinal flora with immune status will be analyzed and compared between these groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Sublimated mare milk | The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2019-11-30
- Completion
- 2020-12-30
- First posted
- 2018-07-20
- Last updated
- 2021-02-08
Locations
1 site across 1 country: Kazakhstan
Source: ClinicalTrials.gov record NCT03594877. Inclusion in this directory is not an endorsement.